Based on this work, direct or indirect EP300inhibitors may be considered as promising therapeutic targets for the treatment of HGPS.The development of next-generation EP300 inhibitors might also be useful for theprevention or treatment of other progeroid syndromes and age-associated diseases as wellas for “normal” aging. The gene discussed is EP300; the disease is Hutchinson-Gilford progeria syndrome.